Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Three-Panel Trial Investigating Safety, Tolerability and Pharmacokinetics of MK-8591 in Healthy Subjects

Trial Profile

A Double-Blind, Placebo-Controlled, Three-Panel Trial Investigating Safety, Tolerability and Pharmacokinetics of MK-8591 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Islatravir (Primary)
  • Indications HIV-1 infections; HIV-2 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 18 Apr 2018 New trial record
    • 07 Mar 2018 Results of pharmacokinetic analysis and the relationship of these data with data from the antiviral efficacy trial in HIV-1 infected subjects, presented at the 25th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top